{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:24:09Z","timestamp":1787185449833,"version":"build-2736575974"},"reference-count":43,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100014660","name":"society for the study of addiction","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014660","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>3,4-methylenedioxymethamphetamine (MDMA) is being investigated as a new therapy for post-traumatic stress disorder (PTSD). With antidepressants as the first-line pharmacotherapy for PTSD, it is important to understand any drug-drug interactions between antidepressants and MDMA. This study aimed to investigate the association between antidepressant use and MDMA fatality using a drug-death database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A retrospective case-control study was performed using a dataset from the National Programme on Substance Use Mortality. Deaths reported between 1997 and May 2023 were extracted. Cases were defined as deaths with MDMA detected and were age- and sex-matched to controls, defined as deaths with no MDMA detected. Cases were analysed by post-mortem (PM) detection of antidepressants and prescription of antidepressants. Conditional logistic regression was performed, adjusted for confounders (polysubstance use and intentionality of death).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 1328 cases and 5312 matched controls for the PM analysis and 840 cases and 3360 matched controls for the prescribed analysis were included. In the PM analysis, after adjusting for potential confounders, antidepressant use was less likely in MDMA fatalities compared to other drug-related deaths (adjusted OR [aOR] 0.595 [95% Confidence interval (CI) 0.491\u20130.722]). In the prescribed analysis, there was no significant association between the prescription of antidepressants and MDMA fatalities (aOR 0.838 [95% CI 0.688\u20131.021]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>An inverse association was found between antidepressant use and MDMA fatality in this retrospective case-control study using a drug-death database.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811261436573","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T05:52:46Z","timestamp":1775541166000},"page":"1352-1360","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of antidepressant use on MDMA fatalities: A matched case-control study using a post-mortem database"],"prefix":"10.1177","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1434-7585","authenticated-orcid":false,"given":"Kirsten L.","family":"Rock","sequence":"first","affiliation":[{"name":"Centre for Pharmaceutical Medicine Research, Institute of Pharmaceutical Science, King\u2019s College London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Rees","sequence":"additional","affiliation":[{"name":"Centre for Pharmaceutical Medicine Research, Institute of Pharmaceutical Science, King\u2019s College London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Morgan","sequence":"additional","affiliation":[{"name":"Centre for Pharmaceutical Medicine Research, Institute of Pharmaceutical Science, King\u2019s College London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4462-1402","authenticated-orcid":false,"given":"Caroline S.","family":"Copeland","sequence":"additional","affiliation":[{"name":"Centre for Pharmaceutical Medicine Research, Institute of Pharmaceutical Science, King\u2019s College London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/002204260803800207"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-009-8064-1"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85389-x"},{"key":"e_1_3_3_5_1","unstructured":"Doblin R. (2017) FDA Grants Breakthrough Therapy Designation for MDMA-Assisted Therapy for PTSD Agrees on Special Protocol Assessment for Phase 3 Trials. Available at: https:\/\/maps.org\/news\/media\/press-release-fda-grants-breakthrough-therapy-designation-for-mdma-assisted-psychotherapy-for-ptsd-agrees-on-special-protocol-assessment-for-phase-3-trials\/ (accessed March 2024)."},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1515\/ijamh-2013-0052"},{"key":"e_1_3_3_7_1","doi-asserted-by":"crossref","unstructured":"Edwards D Csontos J Pascoe M et al. (2022) A Rapid Scoping Review of Harm Reduction Strategies for Ecstasy (MDMA) Users in Recreational Settings [Preprint]. Research Square. Available at: https:\/\/doi.org\/10.21203\/rs.3.rs-2178425\/v1","DOI":"10.21203\/rs.3.rs-2178425\/v1"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.129056"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2018.03.003"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.55.3.3"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66379-9"},{"key":"e_1_3_3_12_1","unstructured":"Health Canada (2023) Notice to stakeholders: Requests to the Special Access Program (SAP) involving psychedelic-assisted psychotherapy. Available at: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/announcements\/requests-special-access-program-psychedelic-assisted-psychotherapy.html (accessed January 2025)."},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.37737\/ace.22005"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2015.08.016"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-025-01337-2"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2009.07.072"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/026988110001400313"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.824288"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199306000-00011"},{"key":"e_1_3_3_20_1","unstructured":"Ministry of Justice (2025) Coroners statistics 2024: England and Wales. Available at: https:\/\/www.gov.uk\/government\/statistics\/coroners-statistics-2024\/coroners-statistics-2024-england-and-wales (accessed February 2026)."},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02565-4"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(18)30135-4"},{"key":"e_1_3_3_23_1","unstructured":"NICE (n.d.) Antidepressant drugs. Available at: https:\/\/bnf.nice.org.uk\/treatment-summaries\/antidepressant-drugs\/ (accessed March 2024)."},{"key":"e_1_3_3_24_1","unstructured":"NICE (2018) Post-traumatic stress disorder [NG116]. Available at: https:\/\/www.nice.org.uk\/guidance\/ng116 (accessed July 2024)."},{"key":"e_1_3_3_25_1","unstructured":"NICE (2024) Depression:Antidepressant dosing and titration. Available at: https:\/\/cks.nice.org.uk\/topics\/depression\/prescribing-information\/antidepressant-dosing-titration\/ (accessed March 2024)."},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000433-199603000-00002"},{"key":"e_1_3_3_27_1","unstructured":"ONS (2023) Drug misuse in England and Wales: Year ending March 2023. Available at: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/crimeandjustice\/articles\/drugmisuseinenglandandwales\/yearendingmarch2023 (accessed July 2024)."},{"key":"e_1_3_3_28_1","article-title":"Analysis of matched case-control studies","volume":"352","author":"Pearce N","year":"2016","unstructured":"Pearce N (2016) Analysis of matched case-control studies. BMJ (Clinical Research Ed.) 352: i969.","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2021.107158"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301491"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001595"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkad002"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/jts.21814"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704230"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-022-06083-y"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.528"},{"issue":"2","key":"e_1_3_3_37_1","first-page":"195","article-title":"Rave drug (ecstasy) and selective serotonin reuptake inhibitor anti-depressants","volume":"42","author":"Singh AN","year":"2000","unstructured":"Singh AN, Catalan J (2000) Rave drug (ecstasy) and selective serotonin reuptake inhibitor anti-depressants. Indian Journal of Psychiatry 42(2): 195\u2013197.","journal-title":"Indian Journal of Psychiatry"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881108092594"},{"key":"e_1_3_3_39_1","volume-title":"Essential Pharmacology: Neuroscientific Basis and Practical Applications","author":"Stahl SM","year":"2000","unstructured":"Stahl SM (2000) Essential Pharmacology: Neuroscientific Basis and Practical Applications, 2nd edn. Cambridge University Press.","edition":"2"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-006-0576-z"},{"key":"e_1_3_3_41_1","volume-title":"Dependence and Withdrawal Associated with Some Prescribed Medicines: An Evidence Review","author":"Taylor S","year":"2019","unstructured":"Taylor S, Annand F, Burkinshaw P, et al. (2019) Dependence and Withdrawal Associated with Some Prescribed Medicines: An Evidence Review. Public Health England."},{"key":"e_1_3_3_42_1","unstructured":"TGA (2023) Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists. Available at: https:\/\/www.tga.gov.au\/news\/media-releases\/change-classification-psilocybin-and-mdma-enable-prescribing-authorised-psychiatrists (accessed January 2025)."},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39335.541782.AD"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-024-01024-8"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261436573","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811261436573","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261436573","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:28:59Z","timestamp":1787182139000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811261436573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1177\/02698811261436573"],"URL":"https:\/\/doi.org\/10.1177\/02698811261436573","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]}}}